Sarepta Therapeutics (SRPT) could meet its revised outlook following a recent cut in its revenue guidance for Elevidys, Oppenheimer said in a Sunday report.
Sarepta cut its Elevidys sales guidance by $550 million at the midpoint in response to heightened caution from patients and caregivers following a patient death, according to the note.
Given the totality of safety and efficacy data, the report said investors are less concerned with the potential for another patient death, seeing recent case as idiosyncratic.
Elevidys being taken off the market is unlikely following supportive comments on cell and gene therapies at the FDA roundtable, the report added.
"We remain confident in management's ability to hit guidance and continue to see shares trading at unique levels we might not see again once overhangs are removed this year," the note said.
Oppenheimer reiterated its outperform rating on the stock and its price target of $123 per share.
Price: 39.95, Change: -3.06, Percent Change: -7.11
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。